Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indonesia Decree Requiring Foreign Drug Makers To Build Local Plants “Disastrous”

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - A decree issued by Indonesia's health minister earlier this month requiring foreign drug manufacturers to build manufacturing plants in the country, or leave, would be disastrous to the industry, an industry leader said

You may also be interested in...

Indonesia On Track For Universal Health Coverage; Ministry Welcomes Foreign Support For Drug Supply

Indonesia is moving ahead with a universal health care program that would be bolstered by an essential drugs list, but premiums and government subsidies still to be determined.

Indonesia Compulsory License Move A Sharp Warning On Cost Pressures In Emerging Markets

Indonesia decree for compulsory license of HIV/AIDS and hepatitis drugs shows prospect of further actions by some countries in Asia could gather speed.

Not Enough Beds To Go Around To Meet Asia’s Rising Demand For Medical Tourism

Frost & Sullivan weighs in on the state of medical tourism in southeast Asia, where some countries see greater opportunities for public-private partnerships.

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts